|
Oct 17
|
AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day
|
|
Oct 10
|
AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain
|
|
Jun 13
|
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
|
|
Apr 10
|
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
|
|
Feb 12
|
AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators
|
|
Dec 7
|
AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14
|
|
Nov 9
|
AlzeCure Publishes its Interim Report for January - September 2023
|
|
Oct 19
|
AlzeCure's Alzheimer Project NeuroRestore ACD856 is also Granted a Patent in Japan
|
|
Oct 17
|
AlzeCure Publishes New Article on the GSM Mechanism Behind Alzstatin Against Alzheimer's Disease
|
|
Sep 20
|
AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference
|
|
Sep 18
|
AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference
|
|
Aug 9
|
AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's
|